In recent years, CAR-T technology has been used to modify CD4+ T cells, and anti-tumor ability does not depend on cytotoxicity, but indirectly acts on tumor cells through the production of interferon-γ (IFN-γ), a large area and a long distance (19). This evidence concerns the gene IFNG and neoplasm.